PY
PYC.AU PYC Therapeutics Ltd
- Market cap
- AUD 1.85B
- P/E
- -
- P/B
- 2.67x
- ROE
- -6.3%
- Dividend yield
- -
- Fundamental score
- 1.8/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is PYC.AU undervalued?
Graham numberThe Graham number of PYC Therapeutics Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PYC Therapeutics Ltd fundamental analysis
8 of 21 checks passedROE 0/2
Low return on equity (-6.3%), below 10%.
ROA 1/1
Return on assets (-6.1%) is above the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (41.1%) is above the industry median (-5.3%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (0.1%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Cash Runway 2/2
Cash covers 9.9 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (2.7x) is below the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
PYC Therapeutics Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PYC Therapeutics Ltd
PYC Therapeutics Limited, a clinical stage drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. It is developing PYC-003, which is in Phase1a/1b multiple ascending dose study for polycystic kidney disease; PYC-002, a Phelan McDermid Syndrome; PYC-001 for the treatment of Phelan-McDermid Syndrome; PYC-001, which is in Phase 1b multiple ascending dose study for autosomal dominant optic …
Full company profilePYC Therapeutics Ltd financial statements
PYC Therapeutics Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 2.76M | 48.5K | 250.00 | 2.40M | 3.07M | 16.0M | 15.8M | 22.1M | 23.5M | - |
| Gross Profit | -1.91M | -32.8K | -131K | 1.85M | 2.45M | 15.2M | 14.9M | 22.1M | 23.5M | -1.20M |
| Operating Income | -4.25M | -9.77M | -7.10M | -9.70M | -21.8M | -30.2M | -39.2M | -38.9M | -53.6M | -82.7M |
| EBITDA | -4.20M | -9.64M | -6.97M | -8.89M | -21.0M | -29.4M | -38.3M | -54.6M | -52.5M | -81.5M |
| Net Income | -1.95M | -7.43M | -4.08M | -6.82M | -17.8M | -13.9M | -22.8M | -37.7M | -50.3M | -43.3M |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | -0.01 | -0.01 | -0.10 | -0.06 |
| Balance Sheet | ||||||||||
| Total Assets | 10.3M | 3.42M | 6.70M | 31.5M | 57.9M | 45.4M | 37.2M | 91.2M | 183M | 709M |
| Total Liabilities | 1.49M | 1.77M | 402K | 1.35M | 4.02M | 5.15M | 8.72M | 10.2M | 13.3M | 15.2M |
| Shareholders' Equity | 8.86M | 1.65M | 6.30M | 28.5M | 53.0M | 39.4M | 27.7M | 80.5M | 170M | 693M |
| Cash & Short-term Investments | 9.94M | 3.15M | 6.18M | 25.4M | 51.5M | 29.1M | 15.6M | 66.9M | 153M | 448M |
| Total Debt | - | - | 798K | 798K | 730K | 944K | 315K | 1.11M | 1.02M | 625K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -1.88M | -6.71M | -5.13M | -5.75M | -11.8M | -21.8M | -24.4M | -38.6M | -51.6M | -44.5M |
| Capital Expenditure | 4.54K | 211K | 458K | 106K | 591K | 387K | 491K | 307K | 975K | 531K |
| Free Cash Flow | -1.89M | -6.92M | -5.58M | -5.85M | -12.4M | -22.2M | -24.9M | -38.9M | -52.5M | -45.1M |
| Ratios | ||||||||||
| ROE | -22.0% | -451.3% | -64.8% | -24.0% | -33.5% | -35.2% | -82.1% | -46.9% | -29.7% | -6.3% |
| ROA | -18.9% | -217.4% | -60.9% | -21.6% | -30.7% | -30.6% | -61.3% | -41.3% | -27.4% | -6.1% |
| Net Profit Margin | -70.6% | -15,340.5% | -1,631,906.8% | -284.8% | -577.9% | -86.4% | -144.2% | -171.0% | -214.1% | - |
| Debt to Equity | - | - | 0.13x | 0.03x | 0.01x | 0.02x | 0.01x | 0.01x | 0.01x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
PYC Therapeutics Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | AUD 10.5M | 0.00 | - |
| 2022 | - | - | - |
| 2021 | AUD 36.3M | 0.01 | - |
| 2020 | AUD 23.5M | 0.01 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Nov 15, 2024.
Who owns PYC Therapeutics Ltd
- Insiders 33.82%
- Institutions 19.11%
- Public & others 47.07%
- Shares outstanding 985M
- Free float 619M
PYC Therapeutics Ltd company profile
- Company name
- PYC Therapeutics Ltd
- Ticker
- PYC.AU
- ISIN
- AU000000PYC7
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- Harry Perkins Institute of Medical Research, Nedlands, WA, Australia, 6009
- Phone
- 61 8 6151 0992
- Website
- pyctx.com
About PYC Therapeutics Ltd
PYC Therapeutics Limited, a clinical stage drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. It is developing PYC-003, which is in Phase1a/1b multiple ascending dose study for polycystic kidney disease; PYC-002, a Phelan McDermid Syndrome; PYC-001 for the treatment of Phelan-McDermid Syndrome; PYC-001, which is in Phase 1b multiple ascending dose study for autosomal dominant optic atrophy; and VP-001 for the treatment of retinitis pigmentosa type 11. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
PYC Therapeutics Ltd management
7- Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.)CEO & Executive Director · born 1983
- Mr. Thomas UlmerChief Financial Officer · born 1978
- Dr. Janya GrainokChief Scientific Officer
- Mr. Jonathan Riley B.Sc., L.L.B.General Counsel & Joint Company Secretary
- Dr. Paula CunninghamChief Development Officer
- Ms. Candice JungeChief Clinical Development Officer
- Mr. Stephen Alan Ledger B.Com.Joint Company Secretary